tbuckley/cabot-search huggingface dataset:
Case 11-2008
Authors: Jay A. Fishman, R. Gilberto Gonzalez, John A. Branda
Journal: New England Journal of Medicine (2008)

A 45-year-old man with end-stage liver disease due to chronic infection with hepatitis B and C viruses and alcohol use was admitted to this hospital for liver transplantation. Nine days later, fever and headache developed, followed by confusion, slurred speech, photophobia, and neck stiffness. A diagnostic procedure was performed.
More Gene Therapies For AIDS Slated To Begin
Authors: S. Jenks
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article More Gene Therapies For AIDS Slated To Begin Get access Susan Jenks Susan Jenks Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 19, 6 October 1993, Pages 1546–1547, https://doi.org/10.1093/jnci/85.19.1546 Published: 06 October 1993
Bone Infarct-Associated Sarcoma Detected on FDG PET/CT
Authors: Sumeet G. Dua, Nilendu Purandare, Sneha Shah, Anshu R. Sharma, Anand A. Zade, Venkatesh Rangarajan
Journal: Clinical Nuclear Medicine (2011)

Secondary sarcomas arising on the background of a bone infarct are extremely uncommon. Based on the knowledge of classic imaging patterns, however, lesions like bone infarcts can be recognized during positron emission tomography/computed tomography studies, which are now being performed increasingly in cancer patients. We demonstrate the detection of this rare entity on positron emission tomography/computed tomography and its correlation on magnetic resonance imaging in a 56-year-old man with asymptomatic multifocal osteonecrosis secondary to steroid treatment for polymyositis.
NHS research authority links approval of trials to registration and publication of results
Authors: Z. Kmietowicz
Journal: BMJ (2013)

Campaigners for transparency of all clinical trial data have welcomed plans set out by the body that oversees research standards in the NHS for the registration of trials and the publication of their results.

The new commitments from the NHS Health Research Authority follow a meeting of stakeholders held on 25 April.1 The proposals include granting ethics approval for clinical trials from September 2013 only to researchers who have agreed a timeframe to register their trial.

The authority was set up in December 2011 to promote and protect the interests of patients in health research. It has said that it would …
Chest Tube Insertion as a Potential Source of False-Positive FDG–Positron Emission Tomographic Results
Authors: HONGMING ZHUANG, MARY E. CUNNANE, NASRIN V. GHESANI, P. DAVID MOZLEY, ABASS ALAVI
Journal: Clinical Nuclear Medicine (2002)

ZHUANG, HONGMING M.D., Ph.D.; CUNNANE, MARY E. M.D.; GHESANI, NASRIN V. M.D.; DAVID MOZLEY, P. M.D.; ALAVI, ABASS M.D. Author Information
OC-054 The Value Of A Ward Liaison Nurse To Improve Endoscopy For In-patients
Authors: A Gaglia, N Taggart, L Williams, L Flavell, J Dahill, N Haslam, R Barkatali, S Sarkar
Journal: Gut (2014)

<h3>Introduction</h3> Endoscopy Inpatients are challenging as they tend to be the sickest patients who require procedures urgently. The numbers fluctuate and there is little provision for capacity in a busy day-case endoscopy unit. At the Royal Liverpool there are &gt;2000 in-patient endoscopic procedures per annum and which are served by 9 per week dedicated in-patient lists. However, these lists were poorly utilised at &lt;50% of time this was due to cancellations and poor scheduling. Waiting times for in-patients were unacceptable. The aim was to improve the in-patient experience of endoscopy and improve efficiency of the in-patient lists. <h3>Methods</h3> In February 2013, an In-patient liaison (B6) was appointed to help coordinate in-patient listing for endoscopy. This involved the triage of patients (including UGI Bleeds and ERCPs), coordinating with the wards and listing of patients. As the focal point of contact for ward teams, advice is given to teams about preparation of patients, as well as consenting patients on the wards ready for lists. Attending ward rounds on a daily basis to AandE, medical admissions unit and Gastroenterology wards means patients are actively listed. The effect was audited with outcomes of list utilisation, improvement patient waiting times and back-filling of lists. <h3>Results</h3> <b>Satisfaction</b> Feedback from the ward staff, doctors and specialist nurses were extremely positive with the role. <b>ERCPS</b> were managed more effectively with reductions in cancellations of patients that did not require them and effective triage to EUS. Also access of patients needing urgent ERCP was much easier due to the value of coordination. <b>UGI Bleeds</b> Were managed more effectively which led to a reduction in the patients that required in-hours and out of hours theatre. <b>Interventional Endoscopy</b> Listing in-patients for complex therapeutic interventions such as stenting and getting tertiary referrals in form other hospitals was significantly improved. <b>Efficiency </b>The list utilisation improved greatly from 64 to 86% in just 8 months. The waiting times (patient scoped within 24 h of referral) improved by 32% for upper GI endoscopy and by 16% for sigmoidoscopy despite a substantial increase in the number of referral s (OGD increase by 13% and sigmoidoscopy by 20%). <h3>Conclusion</h3> An in-patient liaison nurse has been pivotal for improving the quality, and efficiency, of the endoscopy service we offer to in-patients. <h3>Disclosure of Interest</h3> None Declared.
Efficacy of Mammographic Screening of the Elderly: a Case-Referent Study in the Nijmegen Program in The Netherlands
Authors: J. A. A.M. van Dijck, R. Holland, A. L. M. Verbeek, J. H. C. L. Hendriks, M. Mravunac
Journal: JNCI Journal of the National Cancer Institute (1994)

Journal Article Efficacy of Mammographic Screening of the Elderly: a Case-Referent Study in the Nijmegen Program in The Netherlands Get access Jos A. A.M. van Dijck, Jos A. A.M. van Dijck 1Department of Epidemiology, University of Nijmegen and National Expert and Training Center for Breast Cancer Screening, St. Radboud University HospitalNijmegen. The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar Roland Holland, Roland Holland 2Department of Pathology, University of Nijmegen and National Expert and Training Center for Breast Cancer Screening, St. Radboud University HospitalNijmegen. The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar André L. M. Verbeek, André L. M. Verbeek 1Department of Epidemiology, University of Nijmegen and National Expert and Training Center for Breast Cancer Screening, St. Radboud University HospitalNijmegen. The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar Jan H. C. L. Hendriks, Jan H. C. L. Hendriks 3Department of Radiology, University of Nijmegen and National Expert and Training Center for Breast Cancer Screening, St. Radboud University HospitalNijmegen. The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar Marcel Mravunac Marcel Mravunac * 4Department of Pathology, Canisius-Wilhelmina HospitalNijmegen * Correspondence to: J. A. A. M. van Dijck, M.Sc., Department of Epidemiology, University of Nijmegen, P.O. Box 9101, NL-6500 HB Nijmegen, The Netherlands. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 12, 15 June 1994, Pages 934–938, https://doi.org/10.1093/jnci/86.12.934 Published: 15 June 1994 Article history Received: 07 December 1993 Revision received: 14 March 1994 Accepted: 29 March 1994 Published: 15 June 1994
FRI0232 Treatment with angiotensin II receptor-blockers is associated with lower relapse rate and reduced duration of treatment in patients with giant cell arteritis
Authors: M.A. Alba, A. García-Martínez, G. Espigol-Frigole, I. Tavera-Bahillo, S. Prieto-González, M. Corbera-Bellalta, E. Planas-Rigol, J. Hernández-Rodríguez, M.C. Cid
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Nearly 90% of patients with giant cell arteritis (GCA) experience adverse effects related to long-term corticosteroid (CS) treatment. Search for CS-paring agents has been disappointing and only methotrexate has been demonstrated to have modest effect in a meta-analysis of randomized clinical trials. Recently, angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) have been demonstrated to have anti-inflammatory properties. <h3>Objectives</h3> The purpose of this study was to determine whether concomitant treatment with ACEI or ARB is associated with changes in the clinical course of patients with GCA. <h3>Methods</h3> Retrospective study of 94 patients (24 males, 70 females) with biopsy-proven GCA, prospectively screened for aneurysm development and treated by the authors during 5.4±1.4 years (3.8-10.5). Patients were grouped based on their treatment: ACEI (group 1), ARB (group 2) or no ACEI/ARB (group 3). Number of recurrences, time in weeks to reach a stable prednisone dose &lt;10 mg/day with no relapses and aneurysm development were compared among the 3 groups. Chi-square test, ANOVA test and Kaplan-Meyer survival analysis/long-rank test were used for statistical comparison. <h3>Results</h3> During follow-up, 31 patients were treated with ACEI, 12 with ARB and 51 did not receive any of these medications. Patients in the group receiving ARB presented lower frequency of relapses than the other two groups (ARB 25% vs ACEI 61% vs not treated 67%, p=0.021). Patients who had received an ARB required 27±22 weeks to reach a maintenance prednisone dosage &lt;10 mg/day in comparison to 78±82 weeks for patients who received ACEI and 77±88 weeks for patients not treated with ACEI/ARB (p=0.001). We found no differences between groups in the frequency of aneurysm development. <h3>Conclusions</h3> Patients treated with ARB present less frequently relapses and require less time to reach a stable prednisone dose &lt;10 mg day. The possible corticosteroid sparing effect of these agents should be tested in prospective studies. <h3>References</h3> Andersson R, Malmvall BE, Bengtsson BA. Long-term corticosteroid treatment in giant cell arteritis. Acta Med Scand. 1986;220(5):465-9. Proven A, Gabriel SE, Orces C, O’Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum. 2003;49(5):703-8. Mahr AD, Jover JA, Spiera RF, Hernandez-Garcia C, Fernandez-Gutierrez B, Lavalley MP, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007;56(8):2789-97. <h3>Disclosure of Interest</h3> None Declared
Medically Inappropriate Hospital Use in a Pediatric Population
Authors: Kathi J. Kemper
Journal: New England Journal of Medicine (1988)

Abstract To assess the extent of inappropriate hospital use in pediatric inpatients, I modified the Appropriateness Evaluation Protocol (AEP) — developed to assess inappropriate hospital use in adults — to apply to children and used it to evaluate pediatric inpatients retrospectively for every 10th day, from July 1982 to July 1983, at the University of Wisconsin Hospital. Of 1098 patient-days evaluated, 21.4 percent were judged to represent inappropriate hospital use on the basis of the protocol's criteria. The rate of inappropriate use varied according to admitting specialty, ranging from 7 of 70 days (10 percent) for pulmonary medicine to 43 of 61 days (70 percent) for neurology (P<0.005). There was a tendency toward lower rates of inappropriate use in uninsured patients (6 of 44 days [14 percent] vs. 226 of 1038 days [22 percent] in patients with Medicaid or private insurance, P = 0.13), and rates were lower in younger children (74 of 432 days [17 percent] in children ≤5 years of age vs. 162 of 656 days [25 percent] in children >5 years of age, P<0.005). There was no variation according to sex, day of the week, or month. Contrary to expectations, inappropriate use decreased with increased lengths of stay (for stays of 1 day, 8 of 13 days were inappropriate [61 percent]; for stays of 2 to 6 days, 118 of 410 days were inappropriate [29 percent]; for 7 to 13 days, 58 of 291 [20 percent]; and for ≥14 days, 51 of 362 [14 percent], P<0.001). I conclude that there is a substantial rate of inappropriate hospital use in pediatrics and that such use is more likely during short admissions than during long ones. Cost-containment efforts directed at limiting the length of hospitalization may therefore not reduce inappropriate hospital use in this population. (N Engl J Med 1988; 318:1033–7.)
Abstract 5392: Metabolic profiling of castrate-resistant prostate cancer reveals novel role for bile acids in driving castration resistance.
Authors: Divya Chakravarthy, Paul Rivas, Brian Keppler, Jianhua Ruan, Rita Ghosh, Addanki Pratap Kumar
Journal: Cancer Research (2013)

Abstract The 5-year survival for metastatic castrate-resistant prostate cancer patients is less than 30% despite significant progress in the understanding of prostate cancer biology and development of novel therapeutic agents. A major contributing factor for the observed low survival rate of patients with castrate resistant disease is the lack of knowledge regarding metabolic alterations and their underlying contributions during development of castrate-resistant phenotype. Studies conducted in our laboratory and others identified a potential role for 2-methoxyestradiol (2-ME2) to prevent prostate cancer development and progression through inhibition of the anti-apoptotic protein FLIP. The goal of the current study was to identify biochemical changes in response to castration and treatment with 2-ME2 in serum from transgenic adenocarcinoma of mouse prostate (TRAMP) mice using mass spectrometry based global profiling. We identified a total of 54 biochemicals of which 16 increased and 38 decreased in castrated animals compared to sham-castration. Treatment of sham-castrated animals with low and high doses of 2-ME2 altered 91 and 145 biochemicals respectively. On the other hand treatment of castrated animals modulated 89 and 106 biochemicals. Cumulative analysis of these data also identified alteration of 60 biochemicals associated with castration effect, 149 with treatment and 70 interactions between castration and treatment effects. Castration affected metabolites involved in variety of metabolic pathways including lipid, oxidative stress, energetics and bile acid. Given the data showing enhanced expression of FLIP in castrate-resistant prostate tumors and upregulation of bile acids in patients undergoing androgen deprivation therapy, we examined the activation of FLIP in prostate cancer cells in response to deoxycholic acid (DCA). Our data suggests that transcriptional activity of FLIP was higher in PC-3 cells treated with DCA. To the best of our knowledge, this is the first report demonstrating global metabolomic profiling of serum in response to castration and provide a framework for therapeutic targeting of bile acid metabolism. Supported by NIH CA 135451 (APK). Citation Format: Divya Chakravarthy, Paul Rivas, Brian Keppler, Jianhua Ruan, Rita Ghosh, Addanki Pratap Kumar. Metabolic profiling of castrate-resistant prostate cancer reveals novel role for bile acids in driving castration resistance. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5392. doi:10.1158/1538-7445.AM2013-5392 Note: This abstract was not presented at the AACR Annual Meeting 2013 because the presenter was unable to attend.
Abstract 3206: Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy.
Authors: Rong Xu, Yi Huang, Jun Hua Mai, Guo Dong Zhang, Xiao Jing Guo, Xiao Jun Xia, Eugene J Koay, Xue Wu Liu, Mauro Ferrari, Hai Fa Shen
Journal: Cancer Research (2013)

Abstract The ataxia-telangiectasia mutated (ATM) protein plays a central role in DNA damage response and cell cycle checkpoints, and may be a promising target for cancer therapy if normal tissue toxicity could be avoided. Our strategy to target ATM for breast cancer therapy involves the use of liposomal-encapsulated, gene-specific ATM small interfering RNA (siRNA) delivered with a well-characterized porous silicon-based multistage vector (MSV) delivery system (MSV/ATM). Here we have shown that biweekly treatment of MSV/ATM suppressed ATM expression in tumor tissues, and consequently inhibited growth of MDA-MB-231 orthotopic tumor in nude mice. At the therapeutic dosage, neither free liposomal ATM siRNA nor MSV/ATM triggered acute immune response in BALB/c mice, including changes in serum cytokines, chemokines or colony-stimulating factors. Weekly treatments of mice with free liposomal ATM siRNA or MSV/ATM for 4 weeks did not cause significant changes in body weight, hematology, blood biochemistry, or major organ histology. These results indicate that MSV/ATM is biocompatible and efficacious in inhibiting tumor growth, and that further preclinical evaluation is warranted for the development of MSV/ATM as a potential therapeutic agent. Citation Format: Rong Xu, Yi Huang, Jun Hua Mai, Guo Dong Zhang, Xiao Jing Guo, Xiao Jun Xia, Eugene J Koay, Xue Wu Liu, Mauro Ferrari, Hai Fa Shen. Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3206. doi:10.1158/1538-7445.AM2013-3206
VALIDATION OF GASTROINTESTINAL SCINTIGRAPHY WITH Tc-99m-DTPA LABELED TABLETS FOR THE IN VIVO CALCULATION OF THEIR DISSOLUTION RATE.
Authors: J C Maublant, M Sournac, J M Aiache, A Veyre
Journal: Clinical Nuclear Medicine (1986)

INSERM U71, Centre Jean Perrin and Faculty of Pharmacy, Clermont-Ferrand, and Centre de Recherches P Fabre Medicament, Castres, France.
S83 Repeatability and inter-relationships of small airway biomarkers
Authors: S. Gonem, I. Ball, S. Corkill, D. Desai, A. Singapuri, P. Gustafsson, J. Owers-Bradley, C. Brightling, S. Siddiqui
Journal: Thorax (2011)

<h3>Introduction and objectives</h3> There is evidence that the small airways may have an important role in asthma, and a number of physiological techniques have been developed to assess small airway dysfunction. We aimed to determine the within-visit and between-visit repeatability of putative small airway biomarkers, and explore the inter-relationships between them. <h3>Methods</h3> We recruited 17 patients with moderate asthma (GINA 3/4), twelve patients with severe asthma (GINA 5) and fifteen healthy control subjects. Participants attended baseline, 2-week and 3-month visits. At each visit, participants undertook standard pulmonary function tests, multiple breath washout (MBW), impulse oscillometry (IOS) and measurement of exhaled nitric oxide at multiple flow rates. Five healthy subjects and 10 patients with asthma also undertook hyperpolarised helium-3 MRI at the baseline and 3-month visits. This was used to calculate the apparent diffusion coefficient (ADC), a measure of alveolar airspace size. <h3>Results</h3> S<sub>acin</sub>, a MBW marker of acinar airspace disease, showed excellent repeatability in patients with asthma, with intraclass correlation coefficients (ICC) of 0.914, 0.897 and 0.879 for within-visit, 2-week and 3-month repeatability respectively. The IOS small airway markers R5-R20 and AX displayed similarly good repeatability (0.966 [within-visit], 0.905 [2-week] and 0.844 [3-month] for R5-R20, and 0.977 [within-visit], 0.875 [2-week] and 0.855 [3-month] for AX). The 3-month repeatability for ADC was 0.682. Principal components analysis was used to explore the inter-relationships between the small airway biomarkers. Four components were extracted, as shown in Abstract S83 table 1. The highest loading variables on each component were FeNO<sub>200</sub>, NO<sub>alv</sub> and MEF on component 1, R5-R20 and AX on component 2, FVC and RV/TLC on component 3, and Kco (% predicted) and ADC on component 4. Thus, components 1–4 corresponded broadly to the concepts of “airway inflammation”, “frequency dependence of small airway resistance and elastance”, “air trapping” and “alveolar disease” respectively. <h3>Conclusions</h3> The putative small airway markers under investigation are robust and repeatable. Principal components analysis has revealed that the information obtained from multiple tests of airway function may be condensed down to four primary concepts, and that there is significant redundancy among the measurements.
Treating Cancer Pain in Kids Gets New Attention
Authors: F. X. Mahaney
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article Treating Cancer Pain in Kids Gets New Attention Get access Francis X. Mahaney, Jr. Francis X. Mahaney, Jr. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 16, August 1993, Pages 1278–1279, https://doi.org/10.1093/jnci/85.16.1278 Published: 01 August 1993